Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis : As a Model of Crohn's Disease. / Lindebo Holm, Thomas; Poulsen, Steen Seier; Markholst, Helle; Reedtz-Runge, Stine Louise.

In: International Journal of Inflammation, Vol. 2012, 2012, p. 412178.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lindebo Holm, T, Poulsen, SS, Markholst, H & Reedtz-Runge, SL 2012, 'Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease', International Journal of Inflammation, vol. 2012, pp. 412178. https://doi.org/10.1155/2012/412178

APA

Lindebo Holm, T., Poulsen, S. S., Markholst, H., & Reedtz-Runge, S. L. (2012). Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. International Journal of Inflammation, 2012, 412178. https://doi.org/10.1155/2012/412178

Vancouver

Lindebo Holm T, Poulsen SS, Markholst H, Reedtz-Runge SL. Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. International Journal of Inflammation. 2012;2012:412178. https://doi.org/10.1155/2012/412178

Author

Lindebo Holm, Thomas ; Poulsen, Steen Seier ; Markholst, Helle ; Reedtz-Runge, Stine Louise. / Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis : As a Model of Crohn's Disease. In: International Journal of Inflammation. 2012 ; Vol. 2012. pp. 412178.

Bibtex

@article{9087bb9c6b8a4949a2d579fc148a73b4,
title = "Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease",
abstract = "Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.",
author = "{Lindebo Holm}, Thomas and Poulsen, {Steen Seier} and Helle Markholst and Reedtz-Runge, {Stine Louise}",
year = "2012",
doi = "10.1155/2012/412178",
language = "English",
volume = "2012",
pages = "412178",
journal = "International Journal of Inflammation",
issn = "2090-8040",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis

T2 - As a Model of Crohn's Disease

AU - Lindebo Holm, Thomas

AU - Poulsen, Steen Seier

AU - Markholst, Helle

AU - Reedtz-Runge, Stine Louise

PY - 2012

Y1 - 2012

N2 - Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.

AB - Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.

U2 - 10.1155/2012/412178

DO - 10.1155/2012/412178

M3 - Journal article

C2 - 22536543

VL - 2012

SP - 412178

JO - International Journal of Inflammation

JF - International Journal of Inflammation

SN - 2090-8040

ER -

ID: 47486124